Emcure Pharmaceuticals (NSE:EMCURE) Accounts Payable: ₹18,078 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:EMCURE Emcure Pharmaceuticals Ltd NSE:EMCURE
41 GF Score
Price ₹1,960.10
! 5 Warning Signs
View Full Analysis

What is Emcure Pharmaceuticals Accounts Payable?

Emcure Pharmaceuticals NSE:EMCURE +2.57% 41 Accounts Payable is ₹18,078 Mil as of Mar. 2026. GuruFocus rates NSE:EMCURE with a GF Score™ of 41/100. The stock has 5 warning signs investors should review.

Emcure Pharmaceuticals's Accounts Payable for the quarter that ended in Mar. 2026 was ₹18,078 Mil.

Emcure Pharmaceuticals's quarterly Accounts Payable declined from Sep. 2025 (₹17,254 Mil) to Dec. 2025 (₹0 Mil) but then increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹18,078 Mil).

Emcure Pharmaceuticals's annual Accounts Payable increased from Mar. 2024 (₹13,094 Mil) to Mar. 2025 (₹14,796 Mil) and increased from Mar. 2025 (₹14,796 Mil) to Mar. 2026 (₹18,078 Mil).

Emcure Pharmaceuticals Accounts Payable Related Terms

Emcure Pharmaceuticals Accounts Payable Historical Data

* Premium members only.

The historical data trend for Emcure Pharmaceuticals's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Emcure Pharmaceuticals Accounts Payable Chart

Emcure Pharmaceuticals Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Accounts Payable
Get a 7-Day Free Trial 11,251.90 10,861.10 13,093.67 14,795.81 18,077.66

Emcure Pharmaceuticals Quarterly Data
Mar21 Mar22 Mar23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14,795.81 0.00 17,254.43 0.00 18,077.66
NSE:EMCURE
41GF Score
Emcure Pharmaceuticals Ltd NSE:EMCURE
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Emcure Pharmaceuticals Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of ₹18,078 Mil mean?
Emcure Pharmaceuticals (NSE:EMCURE) has a Accounts Payable of ₹18,078 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Emcure Pharmaceuticals and its competitors.
Is Emcure Pharmaceuticals' Accounts Payable too high?
Emcure Pharmaceuticals' current Accounts Payable is ₹18,078 Mil. Overall, Emcure Pharmaceuticals has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does Emcure Pharmaceuticals' Accounts Payable compare to ZTS?
Emcure Pharmaceuticals' Accounts Payable of ₹18,078 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Drug Manufacturers company?
A good Accounts Payable depends on the Drug Manufacturers industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Emcure Pharmaceuticals and its competitors. Emcure Pharmaceuticals's current Accounts Payable is ₹18,078 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emcure Pharmaceuticals stock overvalued right now?
Emcure Pharmaceuticals (NSE:EMCURE) has a current Accounts Payable of ₹18,078 Mil. The current Accounts Payable is ₹18,078 Mil. Emcure Pharmaceuticals' overall GF Score™ is 41/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Emcure Pharmaceuticals (NSE:EMCURE), the current Accounts Payable is ₹18,078 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Emcure Pharmaceuticals Business Description

Other Exchanges 544210:India
Address Plot No. P-1 and P-2, IT-BT Park, Phase II, M.I.D.C., Hinjawadi, Pune, MH, IND, 411 057
Emcure Pharmaceuticals Ltd an Indian pharmaceutical company engaged in developing, manufacturing and globally marketing a range of pharmaceutical products across several therapeutic areas. Its portfolio includes orals including solids, liquid orals and dry syrup/suspensions., injectables such as vials and pre-filled syringes, and forms such as lyophilized & liquid and biotherapeutics. The company operates in Derma, Women's Health, Cardiovascular, Neurology, Oncology, Vaccines, and Anti-infectives. Geographically, it operates in India, Europe, Canada, Vietnam, Dubai, and Other Countries.
41GF Score

Get the complete analysis for NSE:EMCURE

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,960.10
Price